Literature DB >> 10759685

Therapeutic drug monitoring of psychotropic medications.

P B Mitchell1.   

Abstract

Therapeutic drug monitoring (TDM) of a number of psychotropic medications has proven to be of value, enabling minimization of the limitations of considerable genetic variability in their metabolism and the high rates of poor compliance with many psychiatric disorders. Therapeutic ranges have been established for lithium, some of the tricyclic antidepressants, and clozapine. TDM has also been shown to be useful in avoiding toxicity (as many psychotropics have narrow therapeutic indices), particularly that due to interactions with other compounds.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10759685      PMCID: PMC2014933          DOI: 10.1046/j.1365-2125.2000.00174.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  92 in total

1.  Therapeutic drug monitoring of risperidone and 9-hydroxyrisperidone in serum with solid-phase extraction and high-performance liquid chromatography.

Authors:  M C Price; D W Hoffman
Journal:  Ther Drug Monit       Date:  1997-06       Impact factor: 3.681

2.  Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection.

Authors:  M Aravagiri; D Ames; W C Wirshing; S R Marder
Journal:  Ther Drug Monit       Date:  1997-06       Impact factor: 3.681

3.  The use of antidepressants and therapeutic drug monitoring by general practitioners and psychiatrists: findings from a questionnaire survey in two Swedish areas.

Authors:  G Isacsson; U Bergman; D Wasserman; I Redfors; F Sjöqvist
Journal:  Ann Clin Psychiatry       Date:  1996-09       Impact factor: 1.567

Review 4.  Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency.

Authors:  M W Linder; R A Prough; R Valdes
Journal:  Clin Chem       Date:  1997-02       Impact factor: 8.327

Review 5.  Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.

Authors:  P Baumann
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 6.  Will routine therapeutic drug monitoring have a place in clozapine therapy?

Authors:  D J Freeman; L K Oyewumi
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

7.  Duration of lithium treatment and brain lithium concentration in patients with unipolar and schizoaffective disorder--a study with magnetic resonance spectroscopy.

Authors:  U Riedl; A Barocka; H Kolem; J Demling; W P Kaschka; R Schelp; M Stemmler; D Ebert
Journal:  Biol Psychiatry       Date:  1997-04-15       Impact factor: 13.382

8.  Solid-phase extraction and high-performance liquid chromatographic analysis of clozapine and norclozapine in human plasma.

Authors:  D J Freeman; M C Li; K Oyewumi
Journal:  Ther Drug Monit       Date:  1996-12       Impact factor: 3.681

9.  Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges.

Authors:  C VanderZwaag; M McGee; J P McEvoy; O Freudenreich; W H Wilson; T B Cooper
Journal:  Am J Psychiatry       Date:  1996-12       Impact factor: 18.112

10.  Serum lithium levels and psychosocial function in patients with bipolar I disorder.

Authors:  D A Solomon; W R Ristow; M B Keller; J M Kane; A J Gelenberg; J F Rosenbaum; M G Warshaw
Journal:  Am J Psychiatry       Date:  1996-10       Impact factor: 18.112

View more
  7 in total

1.  Biomedical Technologies for in vitro Screening and Controlled Delivery of Neuroactive Compounds.

Authors:  John P Frampton; Michael L Shuler; William Shain; Matthew R Hynd
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2008

Review 2.  Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions.

Authors:  M Gex-Fabry; A E Balant-Gorgia; L P Balant
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 3.  Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring.

Authors:  Etienne Marc Grandjean; Jean-Michel Aubry
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 4.  Pharmacogenetics: the therapeutic drug monitoring of the future?

Authors:  M H Ensom; T K Chang; P Patel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

Review 5.  Lithium in Bipolar Disorder: Optimizing Therapy Using Prolonged-Release Formulations.

Authors:  Paolo Girardi; Roberto Brugnoli; Giovanni Manfredi; Gabriele Sani
Journal:  Drugs R D       Date:  2016-12

6.  Mitochondrial function parameters as a tool for tailored drug treatment of an individual with psychosis: a proof of concept study.

Authors:  Tamara Bar-Yosef; Wessal Hussein; Ofer Yitzhaki; Odeya Damri; Limor Givon; Carmit Marom; Vlada Gurman; Joseph Levine; Yuly Bersudsky; Galila Agam; Dorit Ben-Shachar
Journal:  Sci Rep       Date:  2020-07-23       Impact factor: 4.379

7.  Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients.

Authors:  Yuanyuan Wang; Muh Akbar Bahar; Anouk M E Jansen; Janwillem W H Kocks; Jan-Willem C Alffenaar; Eelko Hak; Bob Wilffert; Sander D Borgsteede
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.